Vascular surgeons propose targeting gut dysbiosis as a novel treatment for intermittent claudication, the debilitating leg pain that limits walking in peripheral artery disease patients. Their framework identifies three interconnected mechanisms: gut microbiome disruption, circadian rhythm dysfunction, and vascular cell aging. Proposed interventions include introducing SCFA-producing bacteria like butyrate and propionate producers, athletic-associated species such as Veillonella atypica and Prevotella, dietary senolytics like o-Vanillin, and time-restricted eating protocols combined with resistance training. This microbiome-centric approach represents a significant departure from traditional claudication management, which relies heavily on antiplatelet medications, statins, and supervised walking programs with limited success rates. The gut-vascular axis concept aligns with emerging research showing how microbial metabolites influence systemic inflammation and endothelial function. However, this remains largely theoretical - the authors present no clinical data, and most supporting evidence comes from tangentially related studies. While the integrative approach addressing multiple pathways simultaneously shows promise, rigorous clinical trials are essential to validate whether microbiome modulation can meaningfully improve walking distance and quality of life in claudication patients. The proposal is innovative but requires substantial proof-of-concept work.